Advanced search
Publication Cover
Pathology Volume 33, 2001 - Issue 3
Submit an article Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Research Article

DISTINCTIVE MICROVILLOUS BRUSH BORDER STAINING WITH HBME-1 DISTINGUISHES PLEURAL MESOTHELIOMAS FROM PULMONARY ADENOCARCINOMAS

Jane E. Dahlstrom, Lesley E. Maxwell, Narelle Brodie, Ibraham M. Zardawi, Sanjiv Jain Department of Anatomical Pathology, ACT Pathology and Canberra Clinical School, University of Sydney, Canberra Hospital, ACT, Australia
Pages 287-291 | Published online: 06 Jul 2009

  • Battifora H. The Pleura. In: Sternberg SS, editor. Diagnostic Surgical Pathology. New York: Lippincott-Raven Press, 1996: 1095-123.
  • Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993; 24: 347-54.
  • Skov BG, Lauritzen AF, Hirsch F, Nielsen HW. The histopathological diagnosis of malignant mesothelioma v pulmonary adenocarcinoma: reproducibility of the histological diagnosis. Histopathology 1994; 24: 553-7.
  • Ordonez NG. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 1999; 112: 75-89.
  • Weiss LM, Battifora H. The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma. Hum Pathol 1993; 24: 345-6.
  • Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999; 30: 313-23.
  • Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JL. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 1998; 32: 462-72.
  • Warhol MI, Hickey WF, Corson JM. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma. Am J Surg Pathol 1982; 6: 307-14.
  • Leong AS-Y, Vernon-Roberts E. The immunohistochemistry of malignant mesothelioma. Pathol Annu 1994; 29: 157-79.
  • Lucas JG, Tuttle SE. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma. J Surg Oncol 1987; 35: 30-4.
  • Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Am J Surg Pathol 1989; 13: 276-91.
  • Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies:thrombomodulin, OV 632 and HMBE-I and their use in the diagnosis of malignant mesothelioma. Histopathology 1996; 29: 209-15.
  • Ordonez NG. The value of antibodies 44-3A6, SM3, HBME-1, and Thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Am J Surg Pathol 1997; 21: 1399-1408.
  • Ordonez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998; 29: 166-9.
  • Ascoli V, Camovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME1 immunostaining in serous effusions. Cytopathology 1997; 8: 328-35.
  • Bateman AC, Al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997; 30: 49-56.
  • Donna A, Betta, P-G, Chiodera P, et at. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 1997; 28: 929-37.
  • MiettinenM, Kovatich AI. HBME-1 a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft tissue and bone tumours. Appl lmmunohistochem 1995; 3: 115-22.
  • Riera IR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a réévaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997; 21: 1409-19.
  • Leers MPG, Aarts MM, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunohistochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998; 32: 209-16.
  • Dako Corporation. Specification sheet: monoclonal mouse anti-human mesothelial cell (HBME-D, code no: M3505. Carpinteria, CA: Dako Corporation, 1996.
  • Kinsel LB, Szabo E, Green GL. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989; 49: 1052-6.
  • Battifora H, McCaughey WTE. Tumors of the Semsal Membranes. Atlas of Tumor Pathology. Third Series, Fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1995: 74.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.